At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
APLM Apollomics Inc
Closed Mourning Day 01-08 16:00:00 EST
10.34
-0.35
-3.27%
盘后10.34
+0.000.00%
18:16 EST
High11.39
Low10.15
Vol11.61K
Open10.71
D1 Closing10.69
Amplitude11.60%
Mkt Cap11.40M
Tradable Cap6.00M
Total Shares1.10M
T/O123.51K
T/O Rate2.00%
Tradable Shares579.88K
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BUZZ-U.S. STOCKS ON THE MOVE-Spire, Copper miners, Abercrombie & Fitch
Apollomics Announces Top-Line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Apollomics, Inc., a biopharmaceutical company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China; and Southbank, Australia.